Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors
by
Zhang, Haiping
, Zhu, Hong
, Geng, Anke
, Chen, Yu
, Qin, Nan
, Tang, Huanyin
, Dai, Binghua
, Xie, Jinru
, Jiang, Ying
, He, Qizhi
, Tan, Rong
, Qiao, Zhibing
, Sun, Xiaoxiang
, Sun, Fang-Lin
, Wang, Chen
, Mao, Zhiyong
, Yang, Jiamei
, Wan, Xiaoping
, Gao, Shaorong
, Chen, Jiayu
in
Animal models
/ Animals
/ Biological Sciences
/ Cancer
/ Carcinoma, Hepatocellular - drug therapy
/ Chromones - pharmacology
/ Deoxyribonucleic acid
/ DNA
/ DNA Breaks, Double-Stranded - drug effects
/ DNA Damage
/ DNA End-Joining Repair - drug effects
/ DNA repair
/ DNA Repair - drug effects
/ DNA-Binding Proteins - metabolism
/ DNA-dependent protein kinase
/ Double-strand break repair
/ Drug Therapy, Combination - methods
/ Gene expression
/ Gene Knock-In Techniques
/ Hepatocellular carcinoma
/ Homologous Recombination
/ Homology
/ Humans
/ Liver cancer
/ Liver Neoplasms - drug therapy
/ Medical Sciences
/ Mice
/ Mice, Nude
/ Morpholines - pharmacology
/ Non-homologous end joining
/ Nucleosomes
/ Phthalazines - pharmacology
/ Piperazines - pharmacology
/ Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors
/ Poly (ADP-Ribose) Polymerase-1 - metabolism
/ Poly(ADP-ribose) polymerase
/ Protein kinase C
/ Recombinational DNA Repair - drug effects
/ Recruitment
/ Repair
/ Therapy
/ Xenograft Model Antitumor Assays
/ Xenografts
/ Xenotransplantation
/ Yeast
2020
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors
by
Zhang, Haiping
, Zhu, Hong
, Geng, Anke
, Chen, Yu
, Qin, Nan
, Tang, Huanyin
, Dai, Binghua
, Xie, Jinru
, Jiang, Ying
, He, Qizhi
, Tan, Rong
, Qiao, Zhibing
, Sun, Xiaoxiang
, Sun, Fang-Lin
, Wang, Chen
, Mao, Zhiyong
, Yang, Jiamei
, Wan, Xiaoping
, Gao, Shaorong
, Chen, Jiayu
in
Animal models
/ Animals
/ Biological Sciences
/ Cancer
/ Carcinoma, Hepatocellular - drug therapy
/ Chromones - pharmacology
/ Deoxyribonucleic acid
/ DNA
/ DNA Breaks, Double-Stranded - drug effects
/ DNA Damage
/ DNA End-Joining Repair - drug effects
/ DNA repair
/ DNA Repair - drug effects
/ DNA-Binding Proteins - metabolism
/ DNA-dependent protein kinase
/ Double-strand break repair
/ Drug Therapy, Combination - methods
/ Gene expression
/ Gene Knock-In Techniques
/ Hepatocellular carcinoma
/ Homologous Recombination
/ Homology
/ Humans
/ Liver cancer
/ Liver Neoplasms - drug therapy
/ Medical Sciences
/ Mice
/ Mice, Nude
/ Morpholines - pharmacology
/ Non-homologous end joining
/ Nucleosomes
/ Phthalazines - pharmacology
/ Piperazines - pharmacology
/ Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors
/ Poly (ADP-Ribose) Polymerase-1 - metabolism
/ Poly(ADP-ribose) polymerase
/ Protein kinase C
/ Recombinational DNA Repair - drug effects
/ Recruitment
/ Repair
/ Therapy
/ Xenograft Model Antitumor Assays
/ Xenografts
/ Xenotransplantation
/ Yeast
2020
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors
by
Zhang, Haiping
, Zhu, Hong
, Geng, Anke
, Chen, Yu
, Qin, Nan
, Tang, Huanyin
, Dai, Binghua
, Xie, Jinru
, Jiang, Ying
, He, Qizhi
, Tan, Rong
, Qiao, Zhibing
, Sun, Xiaoxiang
, Sun, Fang-Lin
, Wang, Chen
, Mao, Zhiyong
, Yang, Jiamei
, Wan, Xiaoping
, Gao, Shaorong
, Chen, Jiayu
in
Animal models
/ Animals
/ Biological Sciences
/ Cancer
/ Carcinoma, Hepatocellular - drug therapy
/ Chromones - pharmacology
/ Deoxyribonucleic acid
/ DNA
/ DNA Breaks, Double-Stranded - drug effects
/ DNA Damage
/ DNA End-Joining Repair - drug effects
/ DNA repair
/ DNA Repair - drug effects
/ DNA-Binding Proteins - metabolism
/ DNA-dependent protein kinase
/ Double-strand break repair
/ Drug Therapy, Combination - methods
/ Gene expression
/ Gene Knock-In Techniques
/ Hepatocellular carcinoma
/ Homologous Recombination
/ Homology
/ Humans
/ Liver cancer
/ Liver Neoplasms - drug therapy
/ Medical Sciences
/ Mice
/ Mice, Nude
/ Morpholines - pharmacology
/ Non-homologous end joining
/ Nucleosomes
/ Phthalazines - pharmacology
/ Piperazines - pharmacology
/ Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors
/ Poly (ADP-Ribose) Polymerase-1 - metabolism
/ Poly(ADP-ribose) polymerase
/ Protein kinase C
/ Recombinational DNA Repair - drug effects
/ Recruitment
/ Repair
/ Therapy
/ Xenograft Model Antitumor Assays
/ Xenografts
/ Xenotransplantation
/ Yeast
2020
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors
Journal Article
Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors
2020
Request Book From Autostore
and Choose the Collection Method
Overview
Understanding differences in DNA double-strand break (DSB) repair between tumor and normal tissues would provide a rationale for developing DNA repair-targeted cancer therapy. Here, using knockin mouse models for measuring the efficiency of two DSB repair pathways, homologous recombination (HR) and nonhomologous end-joining (NHEJ), we demonstrated that both pathways are up-regulated in hepatocellular carcinoma (HCC) compared with adjacent normal tissues due to altered expression of DNA repair factors, including PARP1 and DNA-PKcs. Surprisingly, inhibiting PARP1 with olaparib abrogated HR repair in HCC. Mechanistically, inhibiting PARP1 suppressed the clearance of nucleosomes at DNA damage sites by blocking the recruitment of ALC1 to DSB sites, thereby inhibiting RPA2 and RAD51 recruitment. Importantly, combining olaparib with NU7441, a DNA-PKcs inhibitor that blocks NHEJ in HCC, synergistically suppressed HCC growth in both mice and HCC patient-derived-xenograft models. Our results suggest the combined inhibition of both HR and NHEJ as a potential therapy for HCC.
Publisher
National Academy of Sciences
Subject
/ Animals
/ Cancer
/ Carcinoma, Hepatocellular - drug therapy
/ DNA
/ DNA Breaks, Double-Stranded - drug effects
/ DNA End-Joining Repair - drug effects
/ DNA-Binding Proteins - metabolism
/ DNA-dependent protein kinase
/ Drug Therapy, Combination - methods
/ Homology
/ Humans
/ Liver Neoplasms - drug therapy
/ Mice
/ Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors
/ Poly (ADP-Ribose) Polymerase-1 - metabolism
/ Recombinational DNA Repair - drug effects
/ Repair
/ Therapy
/ Xenograft Model Antitumor Assays
/ Yeast
MBRLCatalogueRelatedBooks
Related Items
Related Items
This website uses cookies to ensure you get the best experience on our website.